Department of Radiation Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Département de Radiothérapie, Institut Bergonie, Bordeaux, France.
Clin Genitourin Cancer. 2017 Dec;15(6):711-716. doi: 10.1016/j.clgc.2017.05.007. Epub 2017 May 10.
The present retrospective study analyzed the tolerance of orthotopic ileal neobladders to radiotherapy by reviewing the acute and late toxicity in patients who underwent postoperative radiotherapy after radical cystectomy/cystoprostatectomy.
A multi-institutional database was created for patients who had undergone radical cystectomy/cystoprostatectomy and neobladder reconstruction, followed by adjuvant radiotherapy (RT). The patient and tumor characteristics were recorded. The RT data were reviewed to determine the treatment technique used, the radiation dose received by the neobladder, and acute and late toxicity evaluated using the Common Terminology Criteria for Adverse Events, version 4.0, scale.
A total of 25 patients were included, with a median age of 64 years. Of the 25 patients, 18 received a dose of 45 to 50.4 Gy. The most common reasons for postoperative radiotherapy were close or positive surgical margins and pT3-pT4 or N+ disease. Ten patients underwent intensity modulated RT. All but 1 patient completed the RT course. Of the patients who completed their RT schedule, none had grade ≥ 3 acute gastrointestinal toxicity. One patient who received concurrent chemotherapy developed grade 3 acute genitourinary toxicity. Three patients reported late grade 1 genitourinary toxicity (frequency of urination, mild leakage at night), with no reports of chronic gastrointestinal toxicity. None of the patients experienced neobladder perforation, leak, or fistula.
The use of moderate doses of pelvic RT (range, 45-50.4 Gy) was well tolerated among the 25 patients who underwent RT after cystoprostatectomy with orthotopic neobladder creation. This finding supports the use of postoperative RT to moderate doses in this patient population when clinically indicated.
本回顾性研究通过分析接受根治性膀胱切除术/膀胱前列腺切除术(RC/CP)后接受术后放疗的患者的急性和晚期毒性,来评估原位回肠新膀胱对放疗的耐受性。
为接受 RC/CP 和新膀胱重建术且随后接受辅助放疗(RT)的患者创建了一个多机构数据库。记录了患者和肿瘤特征。回顾 RT 数据,以确定使用的治疗技术、新膀胱接受的辐射剂量,并使用不良事件常用术语标准,版本 4.0 量表评估急性和晚期毒性。
共纳入 25 例患者,中位年龄为 64 岁。25 例患者中,18 例接受了 45 至 50.4 Gy 的剂量。术后放疗的最常见原因是手术切缘接近或阳性以及 pT3-pT4 或 N+疾病。10 例患者接受了调强放疗。除 1 例患者外,所有患者均完成了 RT 疗程。完成 RT 计划的患者中,无一例发生≥3 级急性胃肠道毒性。1 例接受同步化疗的患者发生 3 级急性泌尿生殖毒性。3 例患者报告了 1 级晚期泌尿生殖毒性(尿频、夜间轻度漏尿),无慢性胃肠道毒性报告。无患者发生新膀胱穿孔、漏液或瘘管。
在接受 RC/CP 联合原位新膀胱重建术后接受 RT 的 25 例患者中,中等剂量盆腔 RT(范围 45-50.4 Gy)的应用耐受性良好。这一发现支持在临床需要时,将术后 RT 应用于该患者群体的中等剂量。